Biacore Life Sciences > LMW Drug discovery

GE Healthcare Life Sciences

Biacore Life Sciences

Choose your destination

You are here: Biacore Life Sciences > LMW Drug discovery

Confidently select the best candidates

back

High quality compound screening and characterization increases productivity and cost-efficiency:

	•		Facilitates more confident selection of compounds (high information content)
	•		Enables analysis of problem targets with unknown or unstable substrates (direct compound-target binding assays)
	•		Efficiently eliminates false-positives (easy provision of selectivity controls)
	•		Low consumption of target proteins compared to alternative methods
	•		Avoids complications and artifacts associated with labelling (SPR detection)

Label-free compound screening	Label-free compound characterization

Which system should I choose?

Good

Better

Best

Biacore 4000
Unmatched productivity

•

Identify selective binders using informative panels of target proteins for successful drug discovery

Biacore T200
Unmatched performance

	•		Develop assays to characterize target: LMW compound interactions
	•		Characterize protein therapeutics and implement QC methods

21 CFR Part 11 Compliance

Downloads
		WP LFIA vaccine piece (1.3 MB)

WP LMW (1.6 MB)